Cigna is a national commercial insurer with broadly typical PA practices for GLP-1 medications.
Type 2 diabetes coverage
Generally covered for T2D. Typical copay $25–$100/month with PA.
Weight management coverage
Variable. Cigna commercial plans cover Wegovy and Zepbound for weight indication with PA; some employer-elected plans exclude weight management.
Cardiovascular indication coverage
Coverage under March 2024 Wegovy CV indication expanding.
OSA indication coverage
Coverage of Zepbound for OSA expanding.
Prior authorization criteria (typical)
Typical PA criteria: BMI thresholds; documented lifestyle modification 3–6 months; comorbidity documentation.
If your plan excludes weight-management drugs
Verify with your specific plan; cash-pay compounded as alternative if PA fails.
How to verify
The most reliable way to verify coverage is to call the member services number on your insurance card and ask: (1) Is [Wegovy/Zepbound/Ozempic/Mounjaro] on my formulary? (2) What tier? (3) What are the prior authorization criteria? (4) What's my expected copay at each tier? Document the date, the rep's name, and any reference number.
Cash-pay alternative
If insurance coverage is unworkable, see our price index for current cash-pay compounded options. NexLife, our editorial pick, lists compounded semaglutide at $95–$109 and tirzepatide at $115–$129 a month depending on plan length (prices as of November 6, 2026); see the NexLife review.